International Pharmacy Costs: Why U.S. Drug Prices Are 278% Higher

RAND’s multinational benchmark found U.S. prescription drug prices at 278% of prices in comparable countries, with branded products far higher still.^[1]

For IPMI carriers and TPAs in 2026, that single number explains why U.S. pharmacy exposure can overwhelm otherwise healthy international medical portfolios unless benefits are engineered with discipline.

---

1) The 278% Gap Is an Underwriting Reality, Not a Headline

The RAND comparison and related Commonwealth Fund analysis both show the U.S. paying materially more than peer systems for many medicines, especially brands and specialty classes.^[1][2] This means a member filling the same therapy in the U.S. versus Europe or Latin America can create multiple-times cost variance.

2) How U.S. Pharmacy Benefits Distort IPMI Loss Ratios

When plans permit unrestricted U.S. pharmacy fill for chronic therapies, claim severity rises through list-price exposure, dispensing channel choice, and weak utilization controls. Employer and payer analyses continue to show pharmacy trend as a key claims-cost pressure point.^[3][4]

3) PBM Strategy for International Payers

• Closed/managed formularies with evidence-driven exceptions
• Reference pricing by therapeutic class and geography
• Mandatory generic/biosimilar first where clinically appropriate
• Site-of-fill optimization (retail, specialty, infusion)

These levers are standard in mature U.S. plans but often underused in IPMI books, where legacy benefit design prioritizes convenience over cost containment.^[5][6]

4) Specialty Drugs: Small Volume, Outsized Spend

IQVIA and payer trend reports continue to show specialty categories driving disproportionate pharmacy spend growth.^[7] For international programs, one unmanaged biologic pathway can wipe out annual margin on an entire member segment.

5) Cross-Border Benefit Engineering That Works

Best-practice designs separate emergency pharmacy access from chronic refill economics. Members should receive urgent supply rapidly while chronic therapy migrates to pre-approved channels with transparent pricing and clinical oversight.^[8][9]

6) KPI Stack for 2026 Pharmacy Governance

Track: gross-to-net per script, specialty share of spend, biosimilar conversion rate, U.S.-fill vs non-U.S.-fill mix, prior-auth turnaround, and member interruption rates. Without this dashboard, payers cannot fix leakage fast enough.

---

The Bottom Line

U.S. drug pricing is structurally higher, and IPMI programs must be designed accordingly. MDabroad helps payers build global pharmacy controls that protect outcomes and margins. For a pharmacy-cost review of your international portfolio, contact us.